Cover Image
市場調查報告書

神經內分泌(類癌)腫瘤 - 開發平台分析

Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 237877
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
神經內分泌(類癌)腫瘤 - 開發平台分析 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014
出版日期: 2014年07月31日 內容資訊: 英文 81 Pages
簡介

神經內分泌(類癌)腫瘤是由神經內分泌系統的細胞所產生。這種功能性的腫瘤會不斷釋放荷爾蒙到人體內,導致許多症狀發生。神經內分泌腫瘤依照原發生部位不同、分泌不同的荷爾蒙,而會產生不同的臨床症狀。包括咳嗽、氣喘、腹瀉、盜汗、低血糖、腹痛及臉紅等,少數病人初期可能不會有任何症狀,醫生多是在進行腸胃道手術或胃腸內視鏡檢查時意外發現,此時腫瘤多已變大,甚至轉移肝臟,壓迫到腸胃、骨頭、神經而造成疼痛、腹瀉、便秘等不適。

本報告提供神經內分泌(類癌)腫瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊,以及最新新聞與發表資訊。

簡介

  • 調查範圍
  • 神經內分泌(類癌)腫瘤概要

治療藥的開發

  • 開發中產品;神經內分泌(類癌)腫瘤 概要
  • 開發中產品;神經內分泌(類癌)腫瘤;開發中產品比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Ipsen S.A.
  • Novartis AG
  • Lexicon Pharmaceuticals, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Camurus AB
  • Vascular Biogenics Ltd.
  • Advanced Accelerator Applications
  • Foresee Pharmaceuticals, LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • telotristat etiprate
  • bevacizumab
  • Lutathera
  • pasireotide LAR
  • ganitumab
  • octreotide acetate
  • SHR-1020
  • VB-111
  • FP-002
  • Peptides for Oncology
  • BIM-23A758

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5256IDB

Summary

Global Markets Direct's, 'Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014', provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuro Endocrine (Carcinoid) Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuro Endocrine (Carcinoid) Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuro Endocrine (Carcinoid) Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuro Endocrine (Carcinoid) Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuro Endocrine (Carcinoid) Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Overview
    • Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis
  • Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Development by Companies
  • Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Neuro Endocrine (Carcinoid) Carcinoma - Products under Development by Companies
  • Neuro Endocrine (Carcinoid) Carcinoma - Products under Investigation by Universities/Institutes
  • Neuro Endocrine (Carcinoid) Carcinoma - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd.
    • Amgen Inc.
    • Ipsen S.A.
    • Novartis AG
    • Lexicon Pharmaceuticals, Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Camurus AB
    • Vascular Biogenics Ltd.
    • Advanced Accelerator Applications
    • Foresee Pharmaceuticals, LLC
  • Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • telotristat etiprate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lutathera - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide LAR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ganitumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHR-1020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIM-23A758 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neuro Endocrine (Carcinoid) Carcinoma - Recent Pipeline Updates
  • Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects
  • Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products
  • Neuro Endocrine (Carcinoid) Carcinoma - Product Development Milestones
    • Featured News & Press Releases
      • Oct 16, 2013: AAA reaches halfway recruitment milestone of cancer patients in Lutathera Pivotal Phase III trial
      • Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome
      • Jun 07, 2013: Cedars-Sinai Launches Phase III Clinical Trial Of Lutathera For Metastatic Carcinoid Cancer Patients
      • Oct 12, 2012: Lexicon Pharma Announces Positive Phase II Trial Results Of Telotristat Etiprate In Carcinoid Syndrome
      • Oct 12, 2012: Lexicon Pharma Initiates Phase III Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome
      • Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment
      • Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US
      • Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome
      • Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors
      • Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H2 2014
  • Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Amgen Inc., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Ipsen S.A., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Novartis AG, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Camurus AB, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Advanced Accelerator Applications, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects, H2 2014
  • Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H2 2014
  • Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top